- Home
- SPOK vs AVIR Comparison
SPOK vs AVIR Comparison
Compare SPOK & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPOK
- AVIR
- Stock Information
- Founded
- SPOK 2004
- AVIR 2012
- Country
- SPOK United States
- AVIR United States
- Employees
- SPOK N/A
- AVIR N/A
- Industry
- SPOK Telecommunications Equipment
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- SPOK Telecommunications
- AVIR Health Care
- Exchange
- SPOK Nasdaq
- AVIR Nasdaq
- Market Cap
- SPOK 306.2M
- AVIR 290.4M
- IPO Year
- SPOK 1992
- AVIR 2020
- Fundamental
- Price
- SPOK $14.86
- AVIR $3.56
- Analyst Decision
- SPOK Hold
- AVIR Hold
- Analyst Count
- SPOK 1
- AVIR 1
- Target Price
- SPOK $15.00
- AVIR $6.88
- AVG Volume (30 Days)
- SPOK 107.4K
- AVIR 152.3K
- Earning Date
- SPOK 11-05-2024
- AVIR 11-06-2024
- Dividend Yield
- SPOK 8.43%
- AVIR N/A
- EPS Growth
- SPOK N/A
- AVIR N/A
- EPS
- SPOK 0.75
- AVIR N/A
- Revenue
- SPOK $138,273,000.00
- AVIR N/A
- Revenue This Year
- SPOK $2.77
- AVIR N/A
- Revenue Next Year
- SPOK $0.94
- AVIR N/A
- P/E Ratio
- SPOK $20.09
- AVIR N/A
- Revenue Growth
- SPOK 1.19
- AVIR N/A
- 52 Week Low
- SPOK $13.24
- AVIR $2.77
- 52 Week High
- SPOK $18.14
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- SPOK 50.13
- AVIR 49.38
- Support Level
- SPOK $14.51
- AVIR $3.31
- Resistance Level
- SPOK $15.25
- AVIR $3.86
- Average True Range (ATR)
- SPOK 0.26
- AVIR 0.12
- MACD
- SPOK 0.04
- AVIR 0.03
- Stochastic Oscillator
- SPOK 60.71
- AVIR 46.90
About SPOK Spok Holdings Inc.
Spok Holdings Inc is a provider of healthcare communications. It reports three market segments namely Healthcare, Government, and Large enterprise. The company provides paging services and software solutions in the United States and abroad. It provides services such as Value-Added Services, Advisory Services, Assessment Services and Adoption Services.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).